Glucagon-like peptide-1 receptor agonist (such as liraglutide or semaglutide) was associated with significant mortality reduction in DM patients affected by coronavirus disease 2019 and anti-inflammatory and immunoregulatory effect was suggested as a potential mechanism which can have similar benefit in prevention of major adverse cardiovascular events [28]. This evidence concerns the gene GLP1R and diabetes mellitus.